header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O3361 INCREASED HIP JOINT PRESSURE ON HIP PERFUSION AND THE EFFECT OF LIPOPOLYSACCHARIDES (LPS)



Abstract

Aims: The present experiment addressed the question whether lipopolysaccharides (LPS), hip joint tamponade or their combination modulate hip perfusion. Methods: 16 immature Danish Landrace pigs of both genders were treated in 3 groups. 4 animals received LPS from escherichia coli intravenously 4 hours previous to hip joint tamponade. 8 pigs underwent the hip operation without previous medication. 4 animals without treatment served as control group. Blood ßow measurement was done by the Radioactive Tracer Microspheres technique. Results: Femoral head epiphyseal blood ßow decreased signiþcantly during hip joint tamponade. Reperfusion occurred to a level not signiþcantly differing from that before ischemia, whereas epiphyses remained ischemic in 2 pigs. The hip joint capsule showed signiþcant hyperperfusion during and after joint tamponade. No signiþcant difference was revealed comparing the LPS-treated and non-treated groups of pigs in all hip regions (p = 0.79, U-test). In addition, in the LPS-group, none of the femoral head epiphyses remained ischemic. Conclusions: LPS and hip joint tamponade, which have separately been discussed as pathomechanic factors of Non Traumatic Femoral Head Necrosis, have been combined in a bifactorial porcine model. Systemic lipopolysacchrides as bacterial endotoxin have no acute effect on regional hip perfusion which would make a consequent osteonecrosis probable. 6hourly hip joint tamponade alone evoked non reperfusion in 2 out of 8 pigs and a prolongation of the 6 hours ischemia might evoke more cases of non reperfusion.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.